MedTrace Logo

Dosimetry of [11C]CHDI-180R and [11C]CHDI-626.

NCT05224115 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2022-05-19

No results posted yet for this study

Summary

A better understanding of the HD pathogenesis mechanisms may lead to a better understanding of disease pathology, progression and development of targeted therapies.

\[11C\]CHDI-00485180-R and \[11C\]CHDI-00485626 are two novel mutant huntingtin aggregate binding PET radioligands which have already demonstrated sensitivity to mutant huntingtin load in animal models. In the current study, the biodistribution and dosimetry of both these ligands will be investigated in young healthy volunteers according to a standard approach, in 3 subjects (including both genders) per tracer.

Conditions

  • Huntington Disease

Interventions

OTHER

[11C]CHDI-00485180-R

Mutant huntingtin aggregate binding PET radioligand.

OTHER

[11C]CHDI-00485626

Mutant huntingtin aggregate binding PET radioligand.

Sponsors & Collaborators

  • CHDI Foundation, Inc.

    collaborator OTHER

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Koen Van Laere, MD, PhD, DSc · UZ/KU Leuven

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-17
Primary Completion
2020-10-13
Completion
2020-10-13

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05224115 on ClinicalTrials.gov